<p>Revolve Wealth Partners LLC 在最近向證券交易委員會提交的文件中表示，在第三季度將其在安進公司（NASDAQ:AMGN - 免費報告）的持股減少了 45.5%。該機構投資者在季度內出售了 12,066 股後，持有 14,461 股該醫療研究公司的股票。Revolve Wealth Partners LLC 在安進的持股在最近一個季度末的價值為 4,081,000 美元。</p>
<ul>
<li>三家醫療巨頭剛剛提高了股息——看看誰支付得最多</li>
</ul>
<p>其他對沖基金和機構投資者也最近調整了對該公司的持股。Fairvoy Private Wealth LLC 在第二季度將其在安進的持股增加了 1.1%。Fairvoy Private Wealth LLC 目前持有 3,171 股該醫療研究公司的股票，價值為 885,000 美元，此前在該期間內又購買了 35 股。Nicholson Wealth Management Group LLC 在第二季度將其在安進的持股增加了 0.6%。Nicholson Wealth Management Group LLC 目前持有 5,918 股該醫療研究公司的股票，價值為 1,652,000 美元，此前在上個季度又購買了 35 股。Crumly &amp; Associates Inc. 在第二季度將其在安進的持股增加了 3.2%。Crumly &amp; Associates Inc. 目前持有 1,146 股該醫療研究公司的股票，價值為 320,000 美元，此前在該期間內又購買了 36 股。Maryland Capital Advisors Inc. 在第二季度將其在安進的持股增加了 5.2%。Maryland Capital Advisors Inc. 目前持有 732 股該醫療研究公司的股票，價值為 204,000 美元，此前在上個季度又購買了 36 股。最後，Lion Street Advisors LLC 在第二季度將其在安進的持股增加了 1.3%。Lion Street Advisors LLC 目前持有 2,773 股該醫療研究公司的股票，價值為 774,000 美元，此前在上個季度又購買了 36 股。對沖基金和其他機構投資者持有該公司 76.50% 的股票。</p>
<h2>內部買賣</h2>
<p>在相關消息中，執行副總裁 Murdo Gordon 於 11 月 12 日星期三出售了 6,879 股該公司的股票。股票以平均價格 336.83 美元出售，總價值為 2,317,053.57 美元。交易完成後，該執行副總裁直接持有公司 41,923 股股票，價值為 14,120,924.09 美元。此次交易使其持股減少了 14.10%。該出售在與證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，資深副總裁 Rachna Khosla 於 11 月 12 日星期三出售了 890 股該股票。股票以平均價格 336.24 美元出售，總價值為 299,253.60 美元。出售後，資深副總裁持有公司 7,082 股股票，價值約為 2,381,251.68 美元。這代表其持股減少了 11.16%。有關此次出售的更多細節可在官方 SEC 披露中找到。內部人士在過去三個月內共出售了 10,908 股公司股票，價值為 3,674,966 美元。內部人士持有該公司 0.69% 的股票。</p>
<h2>分析師評級變動</h2>
<ul>
<li>5 家醫療公司值得關注，因為行業輪動正在全面展開</li>
</ul>
<p>安進已成為多份研究報告的主題。華爾街 Zen 在 12 月 15 日的報告中將安進的評級從 “買入” 上調至 “強力買入”。Guggenheim 在 11 月 6 日的研究報告中將安進的目標價格從 288.00 美元上調至 305.00 美元，並給予該股票 “中性” 評級。大和資本市場在 11 月 18 日的研究報告中將安進的目標價格從 310.00 美元上調至 370.00 美元，並給予該股票 “跑贏大盤” 評級。高盛集團在 11 月 25 日的研究報告中重申了對安進的 “買入” 評級。最後，斯科舍銀行在 11 月 13 日的報告中開始覆蓋安進股票。他們給予該股票 “行業跑贏大盤” 評級，目標價格為 385.00 美元。一位分析師對該股票給予了強力買入評級，十位分析師給予了買入評級，十位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，安進目前的平均評級為 “適度買入”，平均目標價格為 332.85 美元。</p>
<p><strong>查看我們對 AMGN 的最新分析</strong></p>
<h2>安進價格表現</h2>
<ul>
<li>安進股票：在盈利超預期後，新的歷史高點即將到來</li>
</ul>
<p>安進於週二以 331.39 美元開盤。該公司的市值為 1784.5 億美元，市盈率為 25.61，市盈增長比率為 3.11，貝塔值為 0.45。該股票的 50 日移動平均價格為 320.10 美元，200 日移動平均價格為 300.60 美元。安進的 1 年最低價為 257.05 美元，1 年最高價為 346.38 美元。該公司的債務與股本比率為 5.45，流動比率為 1.28，速動比率為 0.99。</p>
<p>安進（NASDAQ:AMGN - 獲取免費報告）最近於 11 月 4 日星期二公佈了季度財報。該醫療研究公司報告季度每股收益為 5.64 美元，超出市場共識預期的 5.01 美元，超出幅度為 0.63 美元。該公司季度收入為 95.6 億美元，而市場共識預期為 89.8 億美元。安進的淨利潤率為 19.47%，股本回報率為 162.59%。安進的季度收入同比增長 12.4%。在去年同期，該公司每股收益為 5.58 美元。安進已將其 2025 財年的指導目標設定為 20.600-21.400 美元每股收益。賣方分析師預測安進將在當前財年發佈 20.62 美元的每股收益。</p>
<h2>安進增加股息</h2>
<p>該公司最近宣佈了季度股息，將於 3 月 6 日（星期五）支付。2 月 13 日（星期五）的登記投資者將獲得每股 2.52 美元的股息。這代表着每年 10.08 美元的年化股息和 3.0% 的股息收益率。這比安進之前的季度股息 2.38 美元有所增加。該股息的除息日為 2 月 13 日（星期五）。安進的派息比率為 73.57%。</p>
<h2>安進簡介</h2>
<p>（免費報告）</p>
<p>安進公司（NASDAQ: AMGN）是一家成立於 1980 年，總部位於加利福尼亞州千橡市的全球生物技術公司。該公司專注於發現、開發、製造和提供針對嚴重疾病的人類治療藥物。安進的工作重點是基於細胞和分子生物學的生物藥物，強調將人類遺傳學和蛋白質科學的進展轉化為患者的治療方案。</p>
<p>安進的商業產品組合歷來包括用於腫瘤學、支持性護理、腎臟病、骨骼健康和心血管疾病的生物製劑。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過安進</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “3 美元人工智能奇蹟股票” 即將騰飛</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>任何費用可以從資本利得税中扣除嗎？</li>
<li>最後一次黃金牛市</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在安進嗎？</h2>
<p>在考慮安進之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而安進並不在名單上。</p>
<p>雖然安進目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

安進

<p>Revolve Wealth Partners LLC 在第三季度將其在安進的持股減少了 45.5%，出售了 12,066 股。內部人士最近出售了 10,908 股，價值 367 萬美元。分析師的評級不一，普遍認為是適度買入，平均目標價為 332.85 美元。安進的股票開盤價為 331.39 美元，市值為 1784.5 億美元</p>

<p>Revolve Wealth Partners LLC cut its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 45.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,461 shares of the medical research company's stock after selling 12,066 shares during the quarter. Revolve Wealth Partners LLC's holdings in Amgen were worth $4,081,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Revolve Wealth Partners LLC 在最近向證券交易委員會提交的文件中表示，在第三季度將其在安進公司（NASDAQ:AMGN - 免費報告）的持股減少了 45.5%。該機構投資者在季度內出售了 12,066 股後，持有 14,461 股該醫療研究公司的股票。Revolve Wealth Partners LLC 在安進的持股在最近一個季度末的價值為 4,081,000 美元。</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家醫療巨頭剛剛提高了股息——看看誰支付得最多</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently modified their holdings of the company. Fairvoy Private Wealth LLC lifted its holdings in Amgen by 1.1% in the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company's stock worth $885,000 after buying an additional 35 shares during the period. Nicholson Wealth Management Group LLC raised its position in shares of Amgen by 0.6% in the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company's stock worth $1,652,000 after acquiring an additional 35 shares in the last quarter. Crumly &amp; Associates Inc. lifted its stake in shares of Amgen by 3.2% in the 2nd quarter. Crumly &amp; Associates Inc. now owns 1,146 shares of the medical research company's stock valued at $320,000 after purchasing an additional 36 shares during the period. Maryland Capital Advisors Inc. boosted its position in shares of Amgen by 5.2% during the second quarter. Maryland Capital Advisors Inc. now owns 732 shares of the medical research company's stock valued at $204,000 after purchasing an additional 36 shares in the last quarter. Finally, Lion Street Advisors LLC boosted its position in shares of Amgen by 1.3% during the second quarter. Lion Street Advisors LLC now owns 2,773 shares of the medical research company's stock valued at $774,000 after purchasing an additional 36 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.</p>
<div class="lb-trans"><p>其他對沖基金和機構投資者也最近調整了對該公司的持股。Fairvoy Private Wealth LLC 在第二季度將其在安進的持股增加了 1.1%。Fairvoy Private Wealth LLC 目前持有 3,171 股該醫療研究公司的股票，價值為 885,000 美元，此前在該期間內又購買了 35 股。Nicholson Wealth Management Group LLC 在第二季度將其在安進的持股增加了 0.6%。Nicholson Wealth Management Group LLC 目前持有 5,918 股該醫療研究公司的股票，價值為 1,652,000 美元，此前在上個季度又購買了 35 股。Crumly &amp; Associates Inc. 在第二季度將其在安進的持股增加了 3.2%。Crumly &amp; Associates Inc. 目前持有 1,146 股該醫療研究公司的股票，價值為 320,000 美元，此前在該期間內又購買了 36 股。Maryland Capital Advisors Inc. 在第二季度將其在安進的持股增加了 5.2%。Maryland Capital Advisors Inc. 目前持有 732 股該醫療研究公司的股票，價值為 204,000 美元，此前在上個季度又購買了 36 股。最後，Lion Street Advisors LLC 在第二季度將其在安進的持股增加了 1.3%。Lion Street Advisors LLC 目前持有 2,773 股該醫療研究公司的股票，價值為 774,000 美元，此前在上個季度又購買了 36 股。對沖基金和其他機構投資者持有該公司 76.50% 的股票。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In related news, EVP Murdo Gordon sold 6,879 shares of the business's stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, SVP Rachna Khosla sold 890 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,908 shares of company stock worth $3,674,966 in the last three months. Insiders own 0.69% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，執行副總裁 Murdo Gordon 於 11 月 12 日星期三出售了 6,879 股該公司的股票。股票以平均價格 336.83 美元出售，總價值為 2,317,053.57 美元。交易完成後，該執行副總裁直接持有公司 41,923 股股票，價值為 14,120,924.09 美元。此次交易使其持股減少了 14.10%。該出售在與證券交易委員會的法律文件中披露，相關信息可在 SEC 網站上找到。此外，資深副總裁 Rachna Khosla 於 11 月 12 日星期三出售了 890 股該股票。股票以平均價格 336.24 美元出售，總價值為 299,253.60 美元。出售後，資深副總裁持有公司 7,082 股股票，價值約為 2,381,251.68 美元。這代表其持股減少了 11.16%。有關此次出售的更多細節可在官方 SEC 披露中找到。內部人士在過去三個月內共出售了 10,908 股公司股票，價值為 3,674,966 美元。內部人士持有該公司 0.69% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家醫療公司值得關注，因為行業輪動正在全面展開</li>
</ul>
</div><p>AMGN has been the subject of a number of research reports. Wall Street Zen upgraded Amgen from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Monday, December 15th. Guggenheim upped their target price on shares of Amgen from $288.00 to $305.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, November 6th. Daiwa Capital Markets increased their price target on shares of Amgen from $310.00 to $370.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, November 18th. The Goldman Sachs Group reissued a &#34;buy&#34; rating on shares of Amgen in a research note on Tuesday, November 25th. Finally, Scotiabank initiated coverage on shares of Amgen in a report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $385.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $332.85.</p>
<div class="lb-trans"><p>安進已成為多份研究報告的主題。華爾街 Zen 在 12 月 15 日的報告中將安進的評級從 “買入” 上調至 “強力買入”。Guggenheim 在 11 月 6 日的研究報告中將安進的目標價格從 288.00 美元上調至 305.00 美元，並給予該股票 “中性” 評級。大和資本市場在 11 月 18 日的研究報告中將安進的目標價格從 310.00 美元上調至 370.00 美元，並給予該股票 “跑贏大盤” 評級。高盛集團在 11 月 25 日的研究報告中重申了對安進的 “買入” 評級。最後，斯科舍銀行在 11 月 13 日的報告中開始覆蓋安進股票。他們給予該股票 “行業跑贏大盤” 評級，目標價格為 385.00 美元。一位分析師對該股票給予了強力買入評級，十位分析師給予了買入評級，十位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，安進目前的平均評級為 “適度買入”，平均目標價格為 332.85 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on AMGN</strong></p>
<div class="lb-trans"><p><strong>查看我們對 AMGN 的最新分析</strong></p>
</div><h2>Amgen Price Performance</h2>
<div class="lb-trans"><h2>安進價格表現</h2>
</div><ul>
<li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>安進股票：在盈利超預期後，新的歷史高點即將到來</li>
</ul>
</div><p>AMGN opened at $331.39 on Tuesday. The firm has a market cap of $178.45 billion, a PE ratio of 25.61, a P/E/G ratio of 3.11 and a beta of 0.45. The stock has a 50-day moving average price of $320.10 and a 200-day moving average price of $300.60. Amgen Inc. has a 1 year low of $257.05 and a 1 year high of $346.38. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99.</p>
<div class="lb-trans"><p>安進於週二以 331.39 美元開盤。該公司的市值為 1784.5 億美元，市盈率為 25.61，市盈增長比率為 3.11，貝塔值為 0.45。該股票的 50 日移動平均價格為 320.10 美元，200 日移動平均價格為 300.60 美元。安進的 1 年最低價為 257.05 美元，1 年最高價為 346.38 美元。該公司的債務與股本比率為 5.45，流動比率為 1.28，速動比率為 0.99。</p>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating the consensus estimate of $5.01 by $0.63. The company had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. Amgen's revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the prior year, the firm posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>安進（NASDAQ:AMGN - 獲取免費報告）最近於 11 月 4 日星期二公佈了季度財報。該醫療研究公司報告季度每股收益為 5.64 美元，超出市場共識預期的 5.01 美元，超出幅度為 0.63 美元。該公司季度收入為 95.6 億美元，而市場共識預期為 89.8 億美元。安進的淨利潤率為 19.47%，股本回報率為 162.59%。安進的季度收入同比增長 12.4%。在去年同期，該公司每股收益為 5.58 美元。安進已將其 2025 財年的指導目標設定為 20.600-21.400 美元每股收益。賣方分析師預測安進將在當前財年發佈 20.62 美元的每股收益。</p>
</div><h2>Amgen Increases Dividend</h2>
<div class="lb-trans"><h2>安進增加股息</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. This is an increase from Amgen's previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen's payout ratio is 73.57%.</p>
<div class="lb-trans"><p>該公司最近宣佈了季度股息，將於 3 月 6 日（星期五）支付。2 月 13 日（星期五）的登記投資者將獲得每股 2.52 美元的股息。這代表着每年 10.08 美元的年化股息和 3.0% 的股息收益率。這比安進之前的季度股息 2.38 美元有所增加。該股息的除息日為 2 月 13 日（星期五）。安進的派息比率為 73.57%。</p>
</div><h2>Amgen Profile</h2>
<div class="lb-trans"><h2>安進簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.</p>
<div class="lb-trans"><p>安進公司（NASDAQ: AMGN）是一家成立於 1980 年，總部位於加利福尼亞州千橡市的全球生物技術公司。該公司專注於發現、開發、製造和提供針對嚴重疾病的人類治療藥物。安進的工作重點是基於細胞和分子生物學的生物藥物，強調將人類遺傳學和蛋白質科學的進展轉化為患者的治療方案。</p>
</div><p>Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.</p>
<div class="lb-trans"><p>安進的商業產品組合歷來包括用於腫瘤學、支持性護理、腎臟病、骨骼健康和心血管疾病的生物製劑。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>The Last Gold Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過安進</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “3 美元人工智能奇蹟股票” 即將騰飛</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>任何費用可以從資本利得税中扣除嗎？</li>
<li>最後一次黃金牛市</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在安進嗎？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮安進之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而安進並不在名單上。</p>
</div><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然安進目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Revolve Wealth Partners LLC 出售了 12,066 股安進公司（Amgen Inc.）的股票